Form 4: Olema Pharmaceuticals' Chief Medical Officer Granted Stock Options

Naseem Zojwalla, Chief Medical Officer of Olema Pharmaceuticals, received stock options for 205,000 shares on February 28, 2025, according to a Form 4 filing.

Summary

• A Form 4 filing reveals that Naseem Zojwalla, the Chief Medical Officer of Olema Pharmaceuticals, Inc. (OLMA), was granted stock options.
• The transaction occurred on February 28, 2025.
• Zojwalla received options to purchase 205,000 shares of Olema Pharmaceuticals' common stock at an exercise price of $4.37 per share.
• The options vest over time, with 25% vesting on February 28, 2026, and the remaining options vesting monthly thereafter over 48 months, contingent upon continued service.
• Following the transaction, Zojwalla directly owns options for 205,000 shares.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The granting of stock options to the Chief Medical Officer aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• It incentivizes the Chief Medical Officer to work towards increasing the company's value, which benefits shareholders.

Key Dates